Savara (SVRA) Amortization of Deferred Charges (2015 - 2026)
Savara (SVRA) reported Amortization of Deferred Charges of $160000.0 for Q1 2026, up 128.57% year-over-year from $70000.0 in Q1 2025, and up 26.98% quarter-over-quarter from $126000.0 in Q4 2025.
Savara (SVRA) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends
Savara (SVRA) has 12 years of Amortization of Deferred Charges data on file, last reported at $160000.0 in Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $160000.0, up 128.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $543000.0 (up 98.9% YoY), and the FY2025 annual result was $453000.0, up 67.16% from the prior year.
- Amortization of Deferred Charges climbed to $160000.0 in Q1 2026 per SVRA's latest filing, from $126000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $160000.0 in Q1 2026 and troughed at $45000.0 in Q2 2022.
- A 5-year average of $87588.2 and a median of $68000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2022 and 2026: Amortization of Deferred Charges plunged 67.15% in 2022, then jumped 128.57% in 2026.
- A 5-year view of Amortization of Deferred Charges shows it stood at $68000.0 in 2022, then changed by 0.0% to $68000.0 in 2023, then changed by 0.0% to $68000.0 in 2024, then surged by 85.29% to $126000.0 in 2025, then rose by 26.98% to $160000.0 in 2026.
- Business Quant data shows SVRA's Amortization of Deferred Charges at $160000.0 in Q1 2026, $126000.0 in Q4 2025, and $128000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160,000.00 |
| Mar 31, 2026 | 160,000.00 |
| Dec 31, 2025 | 126,000.00 |
| Dec 31, 2025 | 126,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Mar 31, 2025 | 70,000.00 |
| Mar 31, 2025 | 70,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 67,000.00 |
| Jun 30, 2024 | 67,000.00 |
| Mar 31, 2024 | 68,000.00 |
| Mar 31, 2024 | 68,000.00 |
| Dec 31, 2023 | 68,000.00 |
| Dec 31, 2023 | 68,000.00 |